Two months after receiving a gene-edited pig heart, David Bennett Sr. passed away at the age of 57 years.
The U.S. Patent and Trademark Office ruled that the use of CRISPR-Cas9 in humans belongs to the Broad Institute of Massachusetts Institute of Technology, not the University of California, Berkeley.
Three companies – Intellia Therapeutics, Editas Medicine and uniQure – are each anticipating a bright 2022 as the promises of gene therapy continue to be realized.
Researchers have unlocked a key mechanism behind the genetic variant which could prove hopeful for new treatments for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
Yvonne Bryson, M.D., an infectious disease researcher at UCLA, presented the case of an American woman who was cured of HIV after receiving a new transplant procedure that leverages donated umbilical cord blood.
Temps are falling and so is investor cash as BioSpace reviewed which biotech companies are scooping up the dollars.
The U.S. Food and Drug Administration granted Emergency Use Authorization for Mammoth Biosciences Inc.’s DETECTR BOOST SARS-CoV-2 Reagent Kit, a first of its kind high-throughput solution that combines the power of CRISPR with laboratory automation for SARS-CoV-2 testing.
Cambridge, Mass.-based Moderna and Emeryville, Calif.-based Metagenomi inked a strategic research and development deal on new gene editing systems for in vivo (in the body) human therapies.
Nearly four months after Intellia Therapeutics – along with partner Regeneron Pharmaceuticals – reinvigorated the CRISPR space with the first-ever clinical evidence that CRISPR gene editing inside the body can be safe and effective, the asset in question was granted Orphan Drug Designation by the U.S. Food and Drug Administration.
Allogene Therapeutics is halting the clinical trial for the company’s AlloCAR T cancer therapy after finding some chromosomal abnormality in a patient.